Clinical Trials Browser

Phase 1/2 × Completed × gilteritinib × Clear all

NCT02310321 2025-09-02

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Phase 1/2 Completed

97 enrolled 30 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02014558 2024-12-03

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

265 enrolled 80 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03730012 2024-11-29

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

11 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02561455 2024-11-19

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Phase 1/2 Completed

9 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute